These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
923 related articles for article (PubMed ID: 27828943)
21. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. Lin H; Wu Y; Chen J; Huang S; Wang Y Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658 [TBL] [Abstract][Full Text] [Related]
22. PI3K Isoform Immunotherapy for Solid Tumours. Scott J; Rees L; Gallimore A; Lauder SN Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853 [TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449 [TBL] [Abstract][Full Text] [Related]
24. Therapy-induced tumour secretomes promote resistance and tumour progression. Obenauf AC; Zou Y; Ji AL; Vanharanta S; Shu W; Shi H; Kong X; Bosenberg MC; Wiesner T; Rosen N; Lo RS; Massagué J Nature; 2015 Apr; 520(7547):368-72. PubMed ID: 25807485 [TBL] [Abstract][Full Text] [Related]
25. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
27. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer. Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728 [TBL] [Abstract][Full Text] [Related]
28. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy. Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C Front Immunol; 2021; 12():754196. PubMed ID: 35003065 [TBL] [Abstract][Full Text] [Related]
29. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma. Schlenker R; Schwalie PC; Dettling S; Huesser T; Irmisch A; Mariani M; Martínez Gómez JM; Ribeiro A; Limani F; Herter S; Yángüez E; Hoves S; Somandin J; Siebourg-Polster J; Kam-Thong T; de Matos IG; Umana P; Dummer R; Levesque MP; Bacac M Med; 2024 Jul; 5(7):759-779.e7. PubMed ID: 38593812 [TBL] [Abstract][Full Text] [Related]
30. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589 [TBL] [Abstract][Full Text] [Related]
32. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655 [TBL] [Abstract][Full Text] [Related]
33. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574 [TBL] [Abstract][Full Text] [Related]
34. PI3Kγ is a molecular switch that controls immune suppression. Kaneda MM; Messer KS; Ralainirina N; Li H; Leem CJ; Gorjestani S; Woo G; Nguyen AV; Figueiredo CC; Foubert P; Schmid MC; Pink M; Winkler DG; Rausch M; Palombella VJ; Kutok J; McGovern K; Frazer KA; Wu X; Karin M; Sasik R; Cohen EE; Varner JA Nature; 2016 Nov; 539(7629):437-442. PubMed ID: 27642729 [TBL] [Abstract][Full Text] [Related]
35. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345 [TBL] [Abstract][Full Text] [Related]